Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Oncternal Discontinues Enrollment In ONCT-216 Study For Soft Tissue Cancer

Oncternal Therapeutics Inc (NASDAQ:ONCT) will deprioritize further development of ONCT-216 to reallocate resources to zilovertamab, and its Phase 3 trial is expected to start in Q3 of 2022. The Company has discontinued enrollment in the Phase 1/2 study evaluating ONCT-216 in relapsed or refractory Ewing sarcoma, a type of tumor that forms in…

Benzinga

Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform

Coeptis Therapeutics Inc (OTC:COEP) has entered into a strategic agreement with Statera Biopharma Inc (NASDAQ:STAB) that gives Coeptis the right to acquire Statera'stoll-like receptor 5 (TLR5) agonist platform, including entolimod. Coeptis will agree to pay Statera Biopharma $6 million and revenue-based milestone payments to be defined in the definitive agreement. TLR5 is an innate immunity…

Benzinga

ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce

ProQR Therapeutics N.V. (NASDAQ:PRQR) has decided to prioritize the development of genetic eye disease candidates and the Axiomer RNA base-editing technology platform. The Company will suspend the development of QR-1123 for autosomal dominant retinitis pigmentosa, QR-504a for Fuchs endothelial corneal dystrophy, and all other Inherited Retinal diseases (IRD)-related research activities. ProQR will implement…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Cannabis And Pancreatic Cancer: Botanical Drug Kills 100% Of Cancer Cells, Research On The Cell Model Reveals

Cannabotech (CNTC.TA), which is involved in the development of a botanical drug based on an extract of the Cyathus striatus fungus and a cannabinoid extract from the cannabis plant, reports that in experiments conducted on a cell model, the fungus extract eliminated 100% of pancreatic cancer cells relatively selectively and…

Benzinga

DEA Sued By Rhode Island Lab Over 'Foot Dragging' On Marijuana Pharmaceutical Licensing, Here's What We Know So Far

Two Rhode Island cannabinoid research laboratories are suing the DEA for standing in the way of what they consider to be the crucial development of pharmaceutical-grade cannabis products for use in clinical trials for the treatment of Multiple Sclerosis and Huntington's Disease.

Benzinga

Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity

Halozyme Therapeutics Inc (NASDAQ:HALO) will acquire Antares Pharma Inc (NASDAQ:ATRS) for $5.60 per share, valuing Antares at approximately $960 million. The transaction is expected to be accretive to Halozyme's 2022 revenue and adjusted earnings and accelerate top-and bottom-line growth through 2027, with multiple growth drivers beyond 2027. Antares' suite of FDA-approved and partner products utilizing…

Benzinga

Outlook poses tough questions for next steps on COVID-19 vaccines - Roll Call

Health care officials face tough questions as they set policy to deal with the next phase of the pandemic and try to get the messaging right.

Roll Call

Read news from The Economist, FT, and more,
with one subscription

BTAI: IGALMI™ Approved by the FDA…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT

Benzinga

Warning to pet owners as common dog bowl cleaning mistake can make them ill

Up to 18% of pet owners never wash their dog's bowls

Liverpool Echo

‘People really need to know’: can we trust beauty products to be safe?

In a shocking new docuseries, the highly unregulated and highly dangerous world of cosmetics is thrust into the spotlight

The Guardian - US

Common dog bowl cleaning mistake putting owners and pets at serious health risk

The Food and Drug Association (FDA) carried out the research to find out more about dog owners' feeding habits and consider the impact of hygiene recommendations on food dish contamination.

Daily Record

FDA Places Clinical Hold On Ocugen's Late-Stage COVID-19 Vaccine Trial

The

Benzinga

What's Going On With Myovant Sciences Stock Today?

Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on the Supplemental New Drug Application for MYFEMBREE for the manag

Benzinga

FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump

The FDA has signed off BioCardia Inc's (NASDAQ:BCDA) Investigational New Drug (IND) application for BCDA-04 to initiate Phase 1/2 trial in adult patients recovering from Acute Respiratory Distress Syndrome (ARDS) due to COVID-19. BCDA-04 is a proprietary allogeneic mesenchymal cell (MSC) that is Neurokinin-1 receptor-positive (NK1R+). The trial is expected to start in…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Daily Brief On Trending Tickers For April 12, 2022: Veru, Kohl's Corporation, BioCardia, And More

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the

Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Here's Why Ocugen Shares Are Falling

Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 5.86% to $2.73 during Tuesday's pre-market session after the company announced that it was informed by the FDA that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN, OCU-002, on clinical hold.

Daily Mirror

Common dog bowl cleaning mistake that could make you ill as well as your pet

The Food and Drug Administration (FDA) has been investigation dog owners' feeding habits and studying its impact on dog food dish contamination - saying they 'poses significant health risk'

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Lifts Partial Clinical Hold On Gilead's MDS, AML Magrolimab Studies

The FDA has

Benzinga

Aeglea Bio Stock Gains On Additional Pegzilarginase Data For Rare Metabolic Disease

Aeglea BioTherapeutics Inc (NASDAQ:AGLE) shared additional data from the PEACE Phase 3 study evaluating Pegzilarginase in Arginase 1 Deficiency. Arginase-1 deficiency is a rare inherited disorder characterized by a complete or partial lack of the enzyme arginase in the liver and red blood cells. Arginase plays a role in the breakdown and removal…

The Guardian - US

Baby formula shortages hit stores across US with some rationing supplies

Product recalls after illnesses and deaths linked to powdered infant formula products combine with supply chain problems

Inverse

Melatonin won't cure your sleep problems — and it might even be harmful

From widely varying melatonin supplement content to limited, temporary efficacy, practicing good sleep hygiene is better for insomnia than melatonin supplements

Benzinga

Eton Pharmaceuticals Names James Gruber Finance Chief

Eton Pharmaceuticals Inc (NASDAQ:ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through May to ensure a smooth transition. Mr. Gruber, most recently, was the U.S. Controller at Horizon Therapeutics (NASDAQ:HZNP) for seven years, where he oversaw…

Benzinga

After Leukemia Trial, FDA Puts Partial Hold On Curis' Lymphoma Study

The FDA has placed a partial clinical hold on Curis Inc's (NASDAQ:CRIS) TakeAim Lymphoma study. The TakeAim Lymphoma study is a Phase 1/2 open-label dose-escalating clinical trial investigating emavusertib in patients with B-cell malignancies. This week's notification extends the partial hold across both lymphoma and leukemia studies. As previously announced, the Company had…

Chicago Sun-Times

Can ‘liquid biopsy’ cancer blood tests live up to promise of saving lives?

Research is under way even as one company touts its blood test to people with no signs of cancer as a way to detect tumors that have no recommended screening method.

1 … 222 223 224 225

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.